Clinical Trials Browser

Recurrence × Specimen Handling × 30 days × Clear all

NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute